Sarepta Therapeutics (SRPT) has provided some details about its drug to treat boys with Duchenne muscular dystrophy or DMD. The company says in the fourth quarter, it recorded sales of $5.4 million for the drug known as Exondys 51. That's better than the analyst consensus. TheStreet's Adam Feuerstein writes the reported sales in the December quarter look good, and "puts to rest the worst-case fear of insurance reimbursement denials and roadblocks preventing any DMD boys from receiving treatment." The drug was approved in mid-September.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.